Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NB003 in advanced gastrointestinal stromal tumor after prior tyrosine kinase inhibitor therapy
CTR20260996Phase 3Active
- Sponsor
- Ningbo NewBay Technology Development Co., Ltd.
- Start
- May 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of betacetylmethadol in gastrointestinal stromal tumor (GIST), sponsored by Ningbo NewBay Technology Development Co., Ltd.. Started May 2026; status: active.
02
Drugs
betacetylmethadol
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on CTR20260996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260996.